– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; …
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) ArriVent …
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025 Expect to …
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 Completed reverse merger …
ORLANDO, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), a premier provider of influencer marketing technology, data, and services for the Creator Economy, reported its financial and operational results for the second quarter …
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, …
Strong Second Quarter 2024 Net Revenues of $6.4 Million, Gross Profit of $4.5 Million and Gross Margin of 70% Second Quarter Operating Income of $1.0 Million Represents Significant Progress Towards Full Year Cash Flow Positive Objective First Half 2024 …
Revenue increases 27% year over year Reports gain of $3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers Now treating patients at the new Puebla, Mexico center Conference Call on August 14th at 6:30 pm ET SAN FRANCISCO, …
SAN ANTONIO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Usio, Inc: (Nasdaq: USIO), a leading FinTech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the second …
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free …
Biodiversity Loss and its Consequences Biodiversity, the variety of living organisms in all habitats, is deteriorating at an unprecedented and alarming rate. Biodiversity collapse jeopardizes the goods and services humans obtain from all ecosystems, with …
Overview As the physical and financial impacts of climate change reach new heights, many institutional investors are addressing climate risks and opportunities in their portfolios with renewed urgency. One of the main ways they do this is by engaging with …
345% growth in Net Income and 62% improvement in Adjusted EBITDA compared to Q2 2023 ROUND ROCK, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (OTCQB: TSSI), a data center services company that integrates AI and other high-performance computing …
CALGARY, Alberta, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce its Q2 2024 financial and operational results. Birchcliff is also pleased to announce that its board of …
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ZoomInfo Technologies Inc. (“ZoomInfo” or “the Company”) (NASDAQ: ZI). Investors who …
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Vicor Corporation (“Vicor” or “the Company”) ( …
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of W.P. Carey Inc. (“W.P. Carey” or “the Company”) (NYSE: WPC). Investors who purchased W.P. …
Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. Q1 '24 Continued gross-to-net …
Charleston, SC, Aug. 14, 2024 (GLOBE NEWSWIRE) -- With concepts shamelessly borrowed from mentors and one from the Bible as well as anecdotes drawn from 22 years on the sidelines, acclaimed rugby coach William Laughlin “Loc” Vetter, M.D., FACS, aka Loc …
Second quarter revenue increased to $13.0 million compared to $12.6 million for the second quarter of 2023. Half year revenue increased by $11.3 million to $25.5 million compared to $14.1 million for the same period of 2023. Boca Raton, FL, Aug. 14, 2024 ( …
04 days 13:06:43
